China SXT Pharmaceuticals Statistics
Share Statistics
China SXT Pharmaceuticals has 3.48M shares outstanding. The number of shares has increased by -66.72% in one year.
| Shares Outstanding | 3.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.43M |
| Failed to Deliver (FTD) Shares | 25.22K |
| FTD / Avg. Volume | 2.27% |
Short Selling Information
The latest short interest is 261.99K, so 7.54% of the outstanding shares have been sold short.
| Short Interest | 261.99K |
| Short % of Shares Out | 7.54% |
| Short % of Float | 7.65% |
| Short Ratio (days to cover) | 0.18 |
Valuation Ratios
The PE ratio is -0.46 and the forward PE ratio is null.
| PE Ratio | -0.46 |
| Forward PE | null |
| PS Ratio | 0.75 |
| Forward PS | null |
| PB Ratio | 0.1 |
| P/FCF Ratio | -0.74 |
| PEG Ratio | n/a |
Enterprise Valuation
China SXT Pharmaceuticals Inc. has an Enterprise Value (EV) of -6.24M.
| EV / Earnings | 2.01 |
| EV / Sales | -3.24 |
| EV / EBITDA | 2.65 |
| EV / EBIT | 2.48 |
| EV / FCF | 3.22 |
Financial Position
The company has a current ratio of 1.6, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.6 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.19 |
| Total Debt / Capitalization | 15.97 |
| Cash Flow / Debt | -0.73 |
| Interest Coverage | -4.62 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -15.17%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -15.17% |
| Revenue Per Employee | 25.71K |
| Profits Per Employee | -41.31K |
| Employee Count | 75 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.7 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -78.38% in the last 52 weeks. The beta is 1.16, so China SXT Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | -78.38% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 44.55 |
| Average Volume (20 Days) | 1.11M |
Income Statement
In the last 12 months, China SXT Pharmaceuticals had revenue of 1.93M and earned -3.10M in profits. Earnings per share was -3.57.
| Revenue | 1.93M |
| Gross Profit | 553.97K |
| Operating Income | -2.52M |
| Net Income | -3.10M |
| EBITDA | -2.35M |
| EBIT | -2.52M |
| Earnings Per Share (EPS) | -3.57 |
Balance Sheet
The company has 12.07M in cash and 2.65M in debt, giving a net cash position of 9.42M.
| Cash & Cash Equivalents | 12.07M |
| Total Debt | 2.65M |
| Net Cash | 9.42M |
| Retained Earnings | -24.71M |
| Total Assets | 23.13M |
| Working Capital | 5.33M |
Cash Flow
In the last 12 months, operating cash flow was -1.93M and capital expenditures -7.06K, giving a free cash flow of -1.94M.
| Operating Cash Flow | -1.93M |
| Capital Expenditures | -7.06K |
| Free Cash Flow | -1.94M |
| FCF Per Share | -2.23 |
Margins
Gross margin is 28.73%, with operating and profit margins of -130.42% and -160.67%.
| Gross Margin | 28.73% |
| Operating Margin | -130.42% |
| Pretax Margin | -160.67% |
| Profit Margin | -160.67% |
| EBITDA Margin | -121.91% |
| EBIT Margin | -130.42% |
| FCF Margin | -100.34% |
Dividends & Yields
SXTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -892.5% |
| FCF Yield | -138.38% |
Analyst Forecast
Currently there are no analyst rating for SXTC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 5, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -1.3 |
| Piotroski F-Score | 4 |